The early winners won big — especially the WFH plays like Zoom and Peloton, and, of course, vaccine makers like Pfizer and Moderna.
When Moderna’s stock price peaked in August of 2021, it was up 2,000% from its IPO.
Moderna’s Covid vaccine remains the primary driver of its revenue, and its other vaccine, one for RSV, is “not likely to be a major player.”Unsurprisingly, then, the short-sellers are piling in hard.
“Moderna’s declining stock price, rising short interest, and increased implied volatility reveal an evolving risk narrative,” the S3 report concludes.
A month ago, when Trump announced RFK Jr. as his pick to head the Department of Health and Human Services, shares of prominent vaccine makers including Moderna, Pfizer and Novavax, fell across the board.
Persons:
CNN Business ’, Heck, BioNTech, it’s, won’t, ”, Moderna’s, “, Donald Trump, Robert F, Kennedy Jr, Kennedy, Mr
Organizations:
CNN Business, New York CNN, Pfizer, Moderna, Bank of America, S3 Partners, CNN, Trump, RFK Jr, of Health, Human Services, Novavax, HHS
Locations:
New York, Cambridge , Massachusetts